0001209191-19-028235.txt : 20190508
0001209191-19-028235.hdr.sgml : 20190508
20190508163509
ACCESSION NUMBER: 0001209191-19-028235
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190506
FILED AS OF DATE: 20190508
DATE AS OF CHANGE: 20190508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davidson David
CENTRAL INDEX KEY: 0001578696
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 19807175
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-06
0
0001293971
bluebird bio, Inc.
BLUE
0001578696
Davidson David
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
Common Stock
2019-05-06
4
M
0
6360
5.5004
A
37976
D
Common Stock
2019-05-06
4
S
0
2700
138.2471
D
35276
D
Common Stock
2019-05-06
4
S
0
2600
139.2437
D
32676
D
Common Stock
2019-05-06
4
S
0
1060
140.0164
D
31616
D
Stock Option (right to buy)
5.5004
2019-05-06
4
M
0
6360
0.00
D
2023-01-16
Common Stock
6360
330
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
The range in prices for the transaction reported on this line was $137.69 to $138.66. The average weighted price was $138.2471. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $138.70 to $139.69. The average weighted price was $139.2437. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $139.70 to $140.53. The average weighted price was $140.0164. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013, April 1, 2013 and May 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, April 1, 2014 and May 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years.
/s/ Jason F. Cole, Attorney-in-Fact
2019-05-08